On June 21st, Gelunhui reported that Jin Cheng Pharmaceuticals (SZ 300233) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd. (referred to as Jincheng Tail), recently received the "Drug GMP Compliance Inspection Notice" issued by the Beijing Municipal Drug Administration. Its declared production lines of oseltamivir phosphate and progesterone API have passed the cGMP compliance inspection.
Oseltamivir phosphate is a prodrug of its active metabolite (oseltamivir carboxylate), which is a selective neuraminidase inhibitor of influenza virus. Currently, the relevant formulations of oseltamivir phosphate in China include capsules, granules, and dry-mixed suspensions. It is mainly used in the treatment of Type A and Type B influenza in adults and children aged one year and older, and the prevention of Type A and Type B influenza in adults and adolescents aged 13 years and older. Currently, the main domestic manufacturers of oseltamivir phosphate API include Shanghai Desano Chemical Pharmaceutical Co., Ltd., Yichang Hec Changjiang Pharmaceutical Co., Ltd., and other companies.
Progesterone is a synthetic estrogen used topically to treat symptoms of vulvar and vaginal atrophy and to accelerate wound healing after vulvar and vaginal surgery or trauma (such as childbirth). The related formulations of domestic progesterone include soft capsules, cream, and vaginal tablets. This product has been clinically used in more than 40 countries for more than 40 years, and is a first-line drug for the treatment of vaginal infections and atrophic vaginitis in many countries. Currently, the main domestic manufacturers of progesterone API include Yabao Pharmaceutical Group Co., Ltd., Beijing Sili'an Pharmaceutical Co., Ltd., and other companies.